Trial for Evaluation of Safety of Escalating Dose Levels of MEDI-507 in Patients for Treatment of at Least Grade II Graft-Versus-Host Disease (GvHD)

NCT00806208 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

34

Enrollment

INDUSTRY

Sponsor class

Conditions

Graft-Versus-Host Disease

Interventions

DRUG: MEDI-507
DRUG: MEDI-507
DRUG: MEDI-507
DRUG: MEDI-507
OTHER: Placebo

Sponsor

MedImmune LLC